Literature DB >> 21308716

Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia?

Susan Voigt1, Friederike Hüttig, Rainer Koch, Stefan Propping, Catharina Propping, Marc-Oliver Grimm, Manfred Wirth.   

Abstract

BACKGROUND: Vaporization of the prostate (e.g., using laser devices) for treatment of benign prostatic hyperplasia does not allow for subsequent histological examination. Therefore, patients should be counseled about the risk of missing an incidental prostate cancer (incPCa). In this study the risk of an incPCa was determined based on all preoperative parameters.
METHODS: Thousand three hundred and fifty seven (04/2004-09/2008) patients underwent transurethral resection of the prostate (TURP) in our department. Cases with less than 10 g removed tissue, PSA >20 ng/ml or with known PCa were excluded. Data of the remaining 1,000 consecutive patients were collected retrospectively and statistically analyzed using SAS.
RESULTS: Mean age was 69.4 (36-96) years, mean PSA 4.41 (0.08-19.5) ng/ml, mean weight of removed tissue 30.9 (10-110) g. An incPCa was detected in 111 cases. Thirty-four out of these were considered to be clinically relevant (relPCa; stage T1b and/or Gleason sum ≥7). In univariate analysis age, volume of the prostate and body mass index correlated with incPCa while age, volume of the prostate and PSA correlated with relPCa. Predictive parameters for a multivariate logistic regression model are age and body mass index for incPCa and age, prostate volume, and number of prior biopsies for relPCa.
CONCLUSIONS: More than 1 in 10 patients undergoing TURP has an incPCa and 3.4% have a relPCa. Patients should be counseled carefully about the risk of missing especially relPCa when undergoing vaporization of the prostate. Our model significantly improves prediction of relPCa compared to PSA and digital examination alone.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308716     DOI: 10.1002/pros.21349

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma.

Authors:  Vincent Misraï; Marie Pasquie; Benoit Bordier; Julien Guillotreau; Alexandre Gryn; Julien Palasse; Eric Bruguière; Benjamin Pradere; Morgan Rouprêt; Kevin C Zorn
Journal:  World J Urol       Date:  2019-05-28       Impact factor: 4.226

2.  HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis.

Authors:  Bernd Rosenhammer; Eva M Lausenmeyer; Roman Mayr; Maximilian Burger; Christian Eichelberg
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

3.  Does mechanical morcellation of large glands compromise incidental prostate cancer detection on specimen analysis? A pathological comparison with open simple prostatectomy.

Authors:  Vincent Misraï; Sébastien Kerever; Marie Pasquie; Benoit Bordier; Julien Guillotreau; Julien Palasse; Virginie Guillotreau; Enrique Rijo; Sébastien Vincendeau; Romain Huet; Romain Mathieu; Benoit Peyronnet; Nathalie Rioux-Leclercq; Eva-Maria Compérat
Journal:  World J Urol       Date:  2018-10-22       Impact factor: 4.226

4.  Incidental finding of prostate cancer in Transurethral Resection of Prostate (TURP) specimens: a retrospective analysis from a Tertiary Care Hospital in Pakistan.

Authors:  Taimoor Khalid Janjua; Muhammad Ali Yousuf; Muhammad Talha Iqbal; Shahbaz Mustafa Memon; Aziz Abdullah; Naveen Faridi; Muhammad Irfan
Journal:  Pan Afr Med J       Date:  2021-05-07

5.  "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP).

Authors:  Annika Herlemann; Kerstin Wegner; Alexander Roosen; Alexander Buchner; Philipp Weinhold; Alexander Bachmann; Christian G Stief; Christian Gratzke; Giuseppe Magistro
Journal:  World J Urol       Date:  2017-05-17       Impact factor: 4.226

6.  Role of Hiraoka's transurethral detachment of the prostate combined with biopsy of the peripheral zone during the same session in patients with repeated negative biopsies in the diagnosis of prostate cancer.

Authors:  Chun-Yu Pan; Bin Wu; Zi-Chuan Yao; Xian-Qing Zhu; Yun-Zhong Jiang; Song Bai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

7.  Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years.

Authors:  Marlon Perera; Nathan Lawrentschuk; Nayomi Perera; Damien Bolton; David Clouston
Journal:  Prostate Int       Date:  2015-11-26

8.  Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era.

Authors:  Brandon Otto; Christopher Barbieri; Richard Lee; Alexis E Te; Steven A Kaplan; Brian Robinson; Bilal Chughtai
Journal:  Adv Urol       Date:  2014-04-29

9.  Should all specimens taken during surgical treatment of patients with benign prostatic hyperplasia be assessed by a pathologist?

Authors:  Michał Andrzej Skrzypczyk; Jakub Dobruch; Lukasz Nyk; Przemysław Szostek; Stanisław Szempliński; Andrzej Borówka
Journal:  Cent European J Urol       Date:  2014-08-18

10.  Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran.

Authors:  Amir-Reza Abedi; Morteza Fallah-Karkan; Farzad Allameh; Arash Ranjbar; Afshin Shadmehr
Journal:  Res Rep Urol       Date:  2018-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.